*ejpmr, 2023, 10(12), 700-703*

**SJIF Impact Factor 6.222**

**EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH**

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

# NOVEL ULTRA-DEFORMABLE VESICULAR LIPID BASED DELIVERY SYSTEM

**Kamal Kishor Singh[1]*, Mohit Khandelwal[2] and Dr. Dilip Agrawal[3]**

[1]Research Scholar, Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur.
[2]Asso. Professor, Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur.
[3]Principal, Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur.

***Corresponding Author: Kamal Kishor Singh**

Research Scholar, Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur.

**Article Received on 21/10/2023** **Article Revised on 11/11/2023** **Article Accepted on 01/12/2023**

## ABSTRACT

Ultra-deformable vesicular lipid-based delivery systems have emerged as a breakthrough in the realm of drug delivery, offering innovative solutions to challenges associated with conventional formulations. These systems are designed to enhance the permeability of drugs across biological barriers, such as skin and mucosa, facilitating improved bioavailability and targeted delivery. This abstract provides an overview of the key features and potential applications of ultra-deformable vesicular lipid-based delivery systems. The versatility of these systems enables the efficient delivery of a wide range of therapeutic agents, including small molecules and macromolecules. Their distinctive ability to deform and traverse biological barriers, such as cell membranes, opens avenues for enhanced drug penetration. This feature is particularly advantageous in transdermal and mucosal drug delivery, where achieving optimal permeation is often a challenge. One of the critical advantages offered by ultra-deformable vesicular lipid-based systems is their potential to significantly improve bioavailability. By surmounting barriers to drug absorption, these systems contribute to enhanced therapeutic efficacy, allowing for reduced dosages and minimized side effects. Furthermore, their adaptability to various formulations ensures compatibility with diverse drugs and therapeutic applications.

**KEYWORDS:** Ultra-deformable, Vesicular, Lipid-based, Biological, Macromolecules.

## INTRODUCTION

In recent years, significant strides have been made in the field of drug delivery, aiming to overcome challenges associated with conventional formulations and enhance the therapeutic efficacy of various drugs. Among these advancements, the emergence of ultra-deformable vesicular lipid-based delivery systems has garnered considerable attention. These innovative systems exhibit unique properties that make them promising candidates for improving drug permeability across biological barriers and optimizing targeted delivery.

### Background

Conventional drug delivery systems often face limitations related to bioavailability, especially when it comes to delivering therapeutic agents through challenging physiological barriers such as the skin, mucosa, or cell membranes. In response to these challenges, researchers have turned to lipid-based vesicular carriers known for their biocompatibility and ability to encapsulate a diverse range of drugs.

### Characteristics of Ultra-Deformable Vesicular Lipid Systems

The distinguishing feature of ultra-deformable vesicular lipid systems lies in their ability to undergo significant deformation without losing integrity. This unique deformability enables these vesicles to traverse through narrow biological pores and enhance drug penetration across various tissues.

These lipid-based systems are typically composed of phospholipids, surfactants, and other lipidic components carefully selected to provide stability, biocompatibility, and flexibility. The resulting vesicles can deform and squeeze through tight intercellular spaces, allowing for improved drug permeation compared to traditional liposomal or vesicular carriers.

Enhanced Permeability: Ultra-deformable vesicular lipid carriers have the ability to deform and squeeze through narrow pores, enabling improved permeability across biological barriers. This property is particularly valuable for enhancing drug absorption through the skin, mucosa, and other cellular membranes.

Improved Bioavailability: By overcoming barriers to drug absorption, these delivery systems contribute to enhanced bioavailability. This means that a higher proportion of the administered drug reaches the systemic circulation, leading to increased therapeutic efficacy and potentially allowing for lower drug dosages.

Targeted Drug Delivery: Ultra-deformable vesicular lipid carriers can be engineered for targeted drug delivery. This allows for the delivery of therapeutic agents to specific tissues or cells, minimizing systemic exposure and reducing the risk of side effects. Targeted drug delivery is especially important in the treatment of localized diseases.

Versatility in Formulation: These delivery systems are versatile and can be adapted for the delivery of various types of drugs, including small molecules, peptides, and macromolecules. The flexibility in formulation makes them suitable for a wide range of therapeutic applications.

Transdermal and Mucosal Delivery: The ability of ultra-deformable vesicular lipid carriers to penetrate through the skin and mucosa makes them particularly relevant for transdermal and mucosal drug delivery. This is advantageous in scenarios where conventional delivery methods face challenges in achieving sufficient drug permeation.

Reduced Side Effects: Enhanced permeability and targeted delivery contribute to minimizing systemic exposure to the drug, which, in turn, can reduce the occurrence of systemic side effects. This is especially important for drugs with a narrow therapeutic index.

Co-Delivery Capabilities: These systems allow for the co-delivery of multiple drugs or therapeutic agents. This is beneficial for combination therapy, where synergistic effects can be achieved, and multiple aspects of a disease can be addressed simultaneously.

Biocompatibility and Stability: Ultra-deformable vesicular lipid carriers are often designed with biocompatible lipid components. This enhances their safety profile, ensuring compatibility with biological systems. Additionally, formulations are designed to maintain stability during storage and transport.

Patient Compliance: The potential for reduced dosages, targeted delivery, and minimization of side effects contributes to improved patient compliance. Patients may find these formulations more convenient and tolerable, leading to better adherence to prescribed treatments.

Innovation in Drug Delivery Technology: The development and utilization of ultra-deformable vesicular lipid-based delivery systems represent a significant advancement in drug delivery technology. This innovation has the potential to address challenges associated with conventional formulations and open new avenues for more effective and patient-friendly drug therapies.

**Preparation Methods**

The preparation of ultra-deformable vesicular lipid-based delivery systems involves various techniques, each tailored to achieve specific characteristics and optimize the vesicle's deformability.

**Thin Film Hydration Method**

- This is a widely employed technique where lipids (phospholipids and surfactants) are dissolved in a volatile organic solvent to form a thin lipid film on the walls of a round-bottom flask.
- The film is then hydrated with an aqueous phase containing the drug of interest, leading to the formation of multilamellar vesicles (MLVs).
- To enhance deformability, the MLVs are subjected to mechanical agitation, such as vortexing or extrusion, resulting in the formation of smaller, more deformable vesicles.

**Reverse Phase Evaporation Method**

- In this method, lipids are dissolved in an organic phase along with an aqueous phase containing the drug.
- The organic phase is then evaporated under reduced pressure, leading to the formation of a concentrated lipid phase.
- Hydration of this concentrated lipid phase results in the formation of vesicles, which are generally smaller and more deformable than those produced by the thin film method.

**Ethanol Injection Method**

- Lipids are dissolved in ethanol, and this lipid solution is rapidly injected into an aqueous phase under stirring.
- The rapid injection and subsequent dilution lead to the formation of vesicles.
- This method is known for producing vesicles with high deformability.

**Supercritical Fluid Technology:**

- Supercritical carbon dioxide is often utilized as a solvent to dissolve lipids and create a supercritical fluid.
- This supercritical fluid is then combined with an aqueous solution containing the drug, resulting in the formation of vesicles.
- This technique allows for precise control over vesicle size and deformability.

**Hydrogel Template Method**

- A hydrogel template is prepared using polymers, and the lipid phase is introduced into the template.
- The template is then subjected to hydration, resulting in the formation of vesicles.

- This method is advantageous for producing vesicles with controlled size and deformability.

**Microfluidic Techniques**
- Microfluidic platforms enable precise control over the mixing of lipid and aqueous phases in microscale channels.
- Continuous flow microfluidics can be employed to generate vesicles with controlled size and deformability.

**Sonication or Probe Sonication**
- Sonication involves the application of high-frequency sound waves to a lipid dispersion in the presence of an aqueous phase.
- This method results in the formation of small and deformable vesicles.

**Extrusion**
- Extrusion involves forcing a lipid suspension through a porous membrane with defined pore sizes.
- This process leads to the formation of unilamellar vesicles with enhanced deformability.

**General Chemical Requirements**

The chemical requirements for ultra-deformable vesicular lipid-based delivery systems involve careful selection and consideration of various components to ensure the desired properties and performance. Here are key chemical requirements:

**Phospholipids**
- Phospholipids are a fundamental component of vesicular lipid carriers. They form the lipid bilayers and contribute to the structural integrity of the vesicles. Common phospholipids include phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine.

**Surfactants**
- Surfactants are often incorporated to enhance vesicle deformability and stability. Surfactants can reduce surface tension and improve the dispersibility of lipids. Common surfactants include Tween, Span, and bile salts.

**Cholesterol**
- Cholesterol is frequently included to modulate the fluidity and stability of the lipid bilayers. It plays a crucial role in controlling the mechanical properties of vesicles, influencing their deformability.

**Hydrophobic and Hydrophilic Drugs**
- The lipid composition must be compatible with the physicochemical properties of the drug payload. Hydrophobic drugs may be encapsulated within the lipid bilayers, while hydrophilic drugs can be entrapped in the aqueous core or within the bilayers in specific formulations.

**Amphiphilic Molecules**
- Amphiphilic molecules, which have both hydrophobic and hydrophilic regions, can be integrated into the vesicle structure to enhance stability and deformability. These molecules contribute to the self-assembly of vesicles.

**pH-Responsive Components**
- In some cases, pH-responsive components may be included to enable triggered drug release in response to changes in pH. This can be particularly useful for targeted drug delivery in specific environments, such as the acidic conditions found in certain diseased tissues.

**Hydration Medium**
- The choice of the aqueous phase used during vesicle formation can impact the properties of the vesicles. The composition of the hydration medium, including salts and other additives, should be carefully considered.

**Stabilizers and Antioxidants**
- Stabilizers, such as antioxidants (e.g., alpha-tocopherol), may be added to protect lipids from oxidation, ensuring the stability of the vesicle formulation during storage.

**Lipid Chain Length and Saturation**
- The length and saturation of lipid chains in the phospholipids influence the fluidity and deformability of vesicles. Tailoring the lipid composition allows for customization of vesicular properties.

**Ligands or Targeting Moieties**
- For targeted drug delivery, specific ligands or targeting moieties may be conjugated to the surface of the vesicles. These ligands can interact with receptors on target cells, enhancing the specificity of drug delivery.

**Polyethylene Glycol (PEG)**
- The incorporation of PEG can improve the circulation time of vesicles by reducing their recognition and clearance by the immune system. PEGylation enhances the stealth properties of vesicles.

**Biodegradable Components**
- To ensure biodegradability, the choice of components should favor those that can be metabolized or eliminated from the body without causing long-term accumulation or toxicity.

**Co-Surfactants**
- Co-surfactants, such as alcohols, may be added to enhance the fluidity and deformability of the lipid bilayers, contributing to the overall performance of the vesicular system.

**Solvents for Drug Loading**

- Depending on the drug's nature, solvents may be required for dissolving hydrophobic drugs during the loading process. The choice of solvents should be compatible with both the drug and the vesicle components.

**Buffers**

- Buffers may be used to maintain a specific pH during the preparation process, ensuring the stability and desired characteristics of the vesicles.

## CONCLUSION

In conclusion, ultra-deformable vesicular lipid-based delivery systems hold great promise for revolutionizing drug delivery strategies. Continued research and development in this field are essential to unlock their full potential, bringing about advancements in therapeutic approaches and ultimately improving the quality of patient care. As these innovative systems progress, they are poised to play a pivotal role in the future of pharmaceutical sciences and healthcare.

## REFERENCES

1. Opatha SAT, Titapiwatanakun V, Chutoprapat R. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics, 2020; 12(9): 12(9): 855. doi: 10.3390/pharmaceutics12090855, PMID 32916782.
2. Ghai I, Chaudhary H, Ghai S, Kohli K, Kr V. A review of transdermal drug delivery using nano-vesicular carriers: transfersomes. Recent Pat Nanomed, 2012; 2(2): 164-71. doi: 10.2174/1877912311202020164.
3. Akram MW, Jamshaid H, Rehman FU, Zaeem M, Khan JZ, Zeb A. Transfersomes: a revolutionary nanosystem for efficient transdermal drug delivery. AAPS PharmSciTech., 2021; 23(1): 7. doi: 10.1208/s12249-021-02166-9, PMID 34853906.
4. Rai S, Pandey V, Rai G. Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: the state of the art. Nano Rev Exp., 2017; 8(1): 1325708. doi: 10.1080/20022727.2017.1325708, PMID 30410704.
5. Chaurasiya P, Ganju E, Upmanyu N, Ray SK, Jain P. Transfersomes: a novel technique for transdermal drug delivery. J Drug Delivery Ther., 2019; 9(1): 279-85. doi: 10.22270/jddt.v9i1.2198.
6. Rai K, Gupta Y, Jain A, Jain SK. Transfersomes: self-optimizing carriers for bioactives. PDA J Pharm Sci Technol, 2008; 62(5): 362-79. PMID 19055232.
7. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst., 1996; 13(3-4): 257-388. doi: 10.1615/critrevtherdrugcarriersyst.v13.i3-4.30, PMID 9016383.
8. Bnyan R, Khan I, Ehtezazi T, Saleem I, Gordon S, O'Neill F. Surfactant effects on lipid-based vesicles properties. J Pharm Sci., 2018; 107(5): 1237-46. doi: 10.1016/j.xphs.2018.01.005. PMID 29336980.
9. Abdelgawad RA, Nasr MA, Hamza MY, Awad GA. Topical and systemic dermal carriers for psoriasis. Int J Curr Pharm Res., 2016; 8(1): 4-9.10.
10. Chauhan P, Tyagi BK. Herbal novel drug delivery systems and transfersomes. J Drug Delivery Ther., 2018; 8(3). doi: 10.22270/jddt.v8i3.1772.
11. Singh S, Vardhan H, Kotla NG, Maddiboyina B, Sharma D, Webster TJ. The role of surfactants in the formulation of elastic liposomal gels containing a synthetic opioid analgesic. Int J Nanomedicine, 2016; 11: 1475-82. doi: 10.2147/IJN.S100253. PMID 27114707.
12. Al Shuwaili AH, Rasool BK, Abdulrasool AA. Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. Eur J Pharm Biopharm, 2016; 102: 101-14. doi: 10.1016/j.ejpb.2016.02.013, PMID 26925505.
13. Nasr A, Abd-Alhaseeb M, Swidan S. Design, optimization and characterization of a transfersomal gel using miconazole nitrate for the treatment of candida skin infections. Qushawy M Pharmaceutics, 2018; 10(1): 26.
14. Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB. Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate. Saudi Pharm J., 2017; 25(7): 1040-6. doi: 10.1016/j.jsps.2017.01.006, PMID 29158713.
15. Bnyan R, Khan I, Ehtezazi T, Saleem I, Gordon S, O'Neill F. Formulation and optimisation of novel transfersomes for sustained release of local anaesthetic. J Pharm Pharmacol., 2019; 71(10): 1508-19. doi: 10.1111/jphp.13149, PMID 31373700.
16. Ruela ALM, Perissinato AG, Lino ME, Mudrik PS, Pereira GR. Evaluation of skin absorption of drugs from topical and transdermal formulations. Braz J Pharm Sci., 2016; 52(3): 527-44. doi: 10.1590/s1984-82502016000300018.